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Anemia is common in patients with cancer or with chronic kidney disease (CKD).
Although the introduction of erythropoiesis-stimulating agents (ESAs) has transformed
the management of anemia, their use has been complicated by a number of factors
including frequent guideline updates, safety concerns and, in the United States, a Risk
Evaluation and Mitigation Strategy (REMS) program, which aimed to ensure that the
benefits of ESAs outweigh the risks. Many previous concerns around ESA use in cancer
and CKD have been addressed by the reassuring results of post-approval studies, and
biosimilar ESAs have been used in Europe for many years, with safety and efficacy
profiles similar to originator products. This review describes the evolution of the use of
ESAs from approval to the present day, discussing results from clinical studies of ESAs
in cancer and CKD, and the influence of these findings on product labeling and guideline
updates. We also discuss the impact of the introduction of ESA biosimilars in Europe,
bringing cost savings and increased access to patients.
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INTRODUCTION
Over 100 years ago, Carnot and Deflandre speculated on the existence of a humoral factor produced
in response to anemia. Rabbits infused with serum from anemic animals showed an increase in red
blood cells, leading to the conclusion that erythropoiesis is regulated by a blood-borne factor (Bunn,
2013). This finding was later confirmed by Erslev (1953) and further studies demonstrated the
Abbreviations: AE, adverse event; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology;
BEST, Breast Cancer Erythropoietin Survival Trial; CHOIR, Correction of Hemoglobin and Outcomes in Renal Insufficiency
study; CIA, chemotherapy-induced anemia; CKD, chronic kidney disease; CREATE, Cardiovascular Risk Reduction by Early
Anemia Treatment with Epoetin-beta study; EMA, European Medicines Agency; ENHANCE, Erythropoietin in Head and
Neck Cancer (ENHANCE) trial; EORTC, European Organisation for Research and Treatment of Cancer; ERBP, European
Renal Best Practice; ESA, erythropoiesis-stimulating agent; ESMO, European Society for Medical Oncology; EU, European
Union; FDA, United States Food and Drug Administration; Hb, hemoglobin; KDIGO, Kidney Disease Improving Global
Outcomes; NCCN, National Comprehensive Cancer Network; NCD, National Coverage Determination; NICE, National
Institute for Health and Care Excellence; NKF-DOQI, National Kidney Foundation Dialysis Outcomes Quality Initiative; OS,
overall survival; PFS, progression-free survival; RAE, reportable adverse event; QoL, quality of life; REMS, Risk Evaluation
and Mitigation Strategy; TREAT, Trial to Reduce Cardiovascular Events with Aranesp Therapy.
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kidneys to be the main source of production of this factor,
now known as erythropoietin (Jacobson et al., 1957; Nathan
et al., 1964). Following identification of the erythropoietin gene,
ESAs were soon being mass-produced, reducing anemia in the
same manner as the human protein erythropoietin, i.e., by
stimulating the proliferation and differentiation of red blood cell
progenitors (burst-forming unit-erythroids and colony-forming
unit-erythroids), and preventing apoptosis (Elliott et al., 2008;
Lodish et al., 2010).
Since the discovery of erythropoietin, ESAs have been used
to treat anemia in various patient groups, including patients
with cancer or CKD, where anemia is a common problem. For
example, the European Cancer Anemia Survey, published in
2004, reported a 39.3% prevalence of anemia in 15,367 cancer
patients at enrollment (Ludwig et al., 2004) and a recent paper
reported the presence of anemia in 3,962 (89.5%) of 4,426 patients
during the course of receiving chemotherapy for solid tumors (Xu
et al., 2016). In non-Hodgkin lymphoma or Hodgkin lymphoma,
30–40% of patients are anemic at diagnosis, while up to 70% of
patients with multiple myeloma are anemic at diagnosis, with
higher rates in myelodysplastic syndromes (Bennett et al., 2010).
An analysis conducted in 2014 in the United States found anemia
to be twice as prevalent in people with CKD (15.4%) than in the
general population (Stauffer and Fan, 2014). Anemia prevalence
increased with stage of kidney disease (8.4% at stage 1 through to
53.4% at stage 5) (Stauffer and Fan, 2014).
While homologous blood transfusion might be a quick way
to alleviate the symptoms of anemia, it is associated with a
number of hazards, including the transmission of infection
and iron overload (Porter, 2001; Jabbour et al., 2008). Since
their introduction to the market in the late 1980s, ESAs have
revolutionized the management of anemia, with improvements
in QoL and mortality associated with the correction of anemia
of CKD patients (Cella and Bron, 1999; Ma et al., 1999). Here,
we review the history of ESA use in patients with cancer or
CKD, discussing changing guidance, benefits, limitations and
appropriate use of ESAs in these patient groups. See Table 1 for a
chronological listing of the key guidelines consulted.
CLINICAL HISTORY OF ESA USE IN
ONCOLOGY, LIMITATIONS AND
GUIDELINES
In 2002, ASCO and ASH published evidence-based guidelines
on the use of epoetin in cancer (Rizzo et al., 2002). These
guidelines recommended use in patients with chemotherapy-
associated anemia with Hb concentrations below 10 g/dL, and
in less severe anemia (Hb 10–12 g/dL) determined by clinical
circumstances. It was suggested that Hb levels can be elevated
to (or near) a concentration of 12 g/dL, with titration of ESAs
to maintain that level, or recommencement of dosing when the
Hb level falls to near 10 g/dL. The guidelines also stated that
insufficient evidence to date support the “normalization” of Hb
levels to above 12 g/dL. The 2002 NCCN guidelines on anemia
recommended that Hb levels below 11 g/dL should prompt
investigation of the symptoms of anemia, and symptomatic
patients treated with ESAs or red blood cell transfusion (Rodgers,
2012). The guidelines recommended a target Hb concentration
of around 12 g/dL and discussed the possible benefits to QoL
associated with ESA use (Rodgers, 2012). In 2003, shortened
survival with ESA treatment in patients with head and neck
cancer was reported in the ENHANCE trial (Henke et al., 2003).
In this trial of 351 patients, one group received epoetin beta in
addition to radiotherapy, while the other group received placebo
with radiotherapy. Eighty-two percent of patients receiving
epoetin reached Hb levels higher than 14 g/dL (women) or
15 g/dL (men) compared with 15% of patients receiving placebo.
Locoregional PFS was worse with epoetin compared with
placebo, and the authors concluded that erythropoietin use in
patients undergoing curative cancer treatment should be studied
in carefully controlled trials (Henke et al., 2003). It is important
to note that ESAs were used off-label, as no patient received
chemotherapy.
The first Cochrane Database meta-analysis on ESA treatment
outcomes in cancer patients (2004) reported a reduction in the
need for blood transfusions with ESA use and a reduction in
the number of units transfused (Bohlius et al., 2004). Also in
2004, the EORTC published guidelines for ESA use in anemic
patients with cancer, which reported a slight elevation in the
risk of thromboembolic events and hypertension in patients
with CIA receiving ESAs (Bokemeyer et al., 2004). Based on
emerging safety data, the FDA, in 2004, recommended target
Hb levels no higher than 12 g/dL (Luksenberg et al., 2004). An
early report on the BEST (Leyland-Jones and BEST Investigators
and Study Group, 2003), showing decreased 12-month survival
among patients with metastatic breast cancer with epoetin alfa
treatment, was discussed in the 2005 NCCN guidelines (Rodgers,
2012), and the full results of the BEST study were published in
2005 (Leyland-Jones et al., 2005). The objective of this trial was
to compare the effect of managing Hb levels between 12 and
14 g/dL with epoetin alfa vs. placebo (where Hb levels were not
managed) in patients with metastatic breast cancer receiving first-
line chemotherapy. Maintaining high Hb levels was associated
with a significantly lower 12-month OS (Leyland-Jones et al.,
2005).
The EORTC guidelines of 2006 reported no clear link between
ESA use in conjunction with chemotherapy or radiotherapy on
survival, local tumor control, time to progression, and PFS,
although a slight elevation in the risk of thromboembolic events
and hypertension in CIA with ESA treatment was again discussed
(Bokemeyer et al., 2007). The guidelines recommended that,
in cancer patients receiving chemotherapy and/or radiotherapy,
ESAs should be initiated at Hb levels of 9–11 g/dL, and the target
Hb concentration should be 12–13 g/dL.
Based on accumulating evidence, in 2007 the FDA issued
a “black box” warning recommending avoidance of Hb levels
greater than 12 g/dL, and the Centers for Medicare and Medicaid
Services made an NCD to limit coverage of ESAs for non-renal
disease indications, which was implemented in 2008 (Center
for Medicare and Medicaid Services, 2007; US Food and Drug
Administration, 2007b, 2017). The 2007 ASCO/ASH guidelines
cautioned against ESA use in cancer patients not receiving
chemotherapy due to reports of increased thromboembolic risks
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TABLE 1 | Guidelines and recommendations reviewed (1997–2018).
Guideline Year Key findings/Recommendations for ESA use
Oncology:
ASCO/ASH 2002 Initiate when Hb < 10 g/dL and in less severe anemia (10–12 g/dL) determined by clinical circumstances. Target no higher than 12 g/dL
NCCN 2002 Target Hb of 12 g/dL
EORTC 2004 Slight elevation in the risk of thromboembolic events and hypertension with ESA use
FDA 2004 Target Hb levels no higher than 12 g/dL
EORTC 2006 Initiate at Hb levels of 9–11 g/dL, target Hb level 12–13 g/dL
FDA 2007 Black box warning to avoid Hb levels greater than 12 g/dL
NCD 2007 Limit ESA use in non-renal disease indications
ASCO/ASH 2007 Initiate when Hb < 10 g/dL, and in less severe anemia (Hb > 10 g/dL and <12 g/dL), use determined by clinical circumstances; cautioned
against ESA use in cancer patients not receiving chemotherapy
FDA 2008 Initiate when Hb is ≥10 g/dL. Removed upper limit of 12 g/dL; patients treated with chemotherapy with curative intent excluded from ESA
treatment
ASCO/ASH 2010 Lowest dose to achieve an increase in Hb to the lowest level for transfusion avoidance. Recommended ESAs as an option in CIA and
Hb < 10 g/dL. Caution advised when used with chemotherapy in diseases associated with increased risk of thromboembolic complications
ESMO 2010 Hb limit of 12 g/dL; ESAs should be carefully reconsidered in patients with a high risk of thromboembolic events, used with caution in liver
disease, and not given to patients with ESA hypersensitivity or poorly controlled hypertension
NCCN 2018 Maintain lowest Hb level to avoid transfusion. Avoid increases >1 g/dL in any 2-week period. Removed need to consult REMS
ESMO 2018 Target Hb level of 12 g/dL, initiated at <10 g/dL (symptomatic anemia) or <8 g/dL (asymptomatic anemia). Iron therapy should be given
before and/or during ESA therapy in the case of absolute or functional iron deficiency. No clinical evidence for an effect of ESAs on
stimulating disease progression or relapse when used within label in cancer patients
Nephrology:
NKF-DOQI 1997 Target Hb level of 11–12 g/dL
FDA 2007 Black box warning recommending maintenance of Hb levels within the range of 10–12 g/dL for anemic patients with CKD
ERBP 2010 Target Hb level of 11–12 g/dL in CKD patients, do not intentionally exceed 13 g/dL
FDA 2011 Removed target Hb range of 10–12 g/dL; recommended use of the lowest ESA dose to reduce the need for transfusions
KDIGO 2012 For CKD patients with Hb concentration ≥ 10.0 g/dL, ESA therapy should not be initiated. Upper target limit of 11.5 g/dL. Individualization
of therapy will be necessary because some patients may have improvements in QoL at Hb concentrations above 11.5 g/dL and will be
prepared to accept the risks
NICE 2015 Target Hb range of 10–12 g/dL
Renal Association 2017 Target Hb range of 10–12 g/dL
ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; ERBP, European Renal Best Practice; ESMO, European Society for Medical
Oncology; FDA, United States Food and Drug Administration; KDIGO, Kidney Disease Improving Global Outcomes; NCCN, National Comprehensive Cancer Network;
NCD, National Coverage Determination; NICE, National Institute for Health and Care Excellence; NKF-DOQI, National Kidney Foundation Dialysis Outcomes Quality
Initiative; REMS, Risk Evaluation and Mitigation Strategy.
and decreased survival in such situations (Rizzo et al., 2008).
ESAs were recommended as a treatment option in CIA when
the Hb level approached or fell below 10 g/dL, and in less severe
anemia (Hb > 10 g/dL and < 12 g/dL), with use determined
by clinical circumstances. In myeloma, non-Hodgkin lymphoma,
or chronic lymphocytic leukemia, the advice was to begin
treatment with chemotherapy and/or corticosteroids and observe
the hematologic outcomes achieved through tumor reduction
before considering epoetin (Rizzo et al., 2008).
In 2008, the FDA lowered the Hb target at which to
initiate ESA treatment to less than 10 g/dL and removed “. . .or
exceeds 12 g/dL” from its guidance, and patients treated with
chemotherapy with curative intent were excluded from ESA
treatment (Hagerty, 2008). The next year, a Cochrane Database
meta-analysis reported an increase in on-study mortality and
worsened OS associated with ESAs (Bohlius et al., 2009). The
2010 ASCO/ASH guidelines advised that the lowest dose to
achieve an increase in Hb to the lowest level required to avoid
transfusions should be used (Rizzo et al., 2010). These guidelines
recommended ESAs as an option for patients with CIA and Hb
concentration lower than 10 g/dL, and advised caution when
using with chemotherapeutic agents in diseases associated with
increased risk of thromboembolic complications (Rizzo et al.,
2010).
In 2010, ESMO released clinical practice guidelines for ESA
use in treating anemia in cancer patients. The guidelines advised
that Hb levels should not exceed 12 g/dL, and that ESAs
should be carefully reconsidered in patients with a high risk
of thromboembolic events, used with caution in liver disease,
and not given to patients with ESA hypersensitivity or poorly
controlled hypertension (Schrijvers et al., 2010). The guidelines
concluded that the evidence of the influence of ESAs on tumor
progression and OS in anemic cancer patients was unclear.
The ESA REMS plan was implemented by the FDA in 2010.
This was a process aimed at ensuring that the benefits outweigh
the risks when prescribing ESAs, although REMS did not apply to
CKD patients. Healthcare providers and hospitals were required
to become certified in the program, provide counseling to each
patient, and have patients complete a Patient and Healthcare
Provider Acknowledgement Form before treatment. By 2011,
Frontiers in Pharmacology | www.frontiersin.org 3 January 2019 | Volume 9 | Article 1498
fphar-09-01498 January 2, 2019 Time: 18:19 # 4
Aapro et al. History of Erythropoiesis-Stimulating Agents
following the “black box” warning, the NCD, and REMS, there
had been a decline in the proportion of patients receiving
chemotherapy using ESAs, an increase in the proportion of
patients where ESAs were initiated at Hb levels <10 g/dL,
and an increase in the proportion of patients receiving ESAs
at dosages consistent with product labeling (US Food and
Drug Administration, 2017). An analysis of total ESA claims
from the merged South Carolina Medicaid Cancer Registry
dataset for cancer patients on chemotherapy from 2002 to 2012
reported a decline in ESA claims from 2006 through 2012,
showing reductions over the period encompassing the “black
box” warning of 2007, the NCD, and the introduction of REMS
(Figure 1) (Noxon et al., 2014). Claims peaked at 2,243 in
2006, but this figure had decreased to 714 by 2008. A monthly
breakdown showed a peak of 250 claims in May 2006, decreasing
to 7 by December 2012. Another in-depth report involved an
analysis of electronic health records in the Cerner Database
from January 1, 2005, to June 30, 2011, reporting the use of
epoetin alfa and darbepoetin alfa in CKD and chronic anemia.
Between these dates, there were 111,363 encounters of ESA use,
representing 86,763 patients admitted to Cerner Health. Overall,
ESA use in this sample decreased by 33% over the period studied,
with the biggest reduction seen in 2009, following the NCD of
2008 (Figure 2) (Seetasith, 2013). At the time of writing, we
were unable to source detailed relevant data post-2012 on these
measures of ESA use.
Following implementation of the REMS program, a number
of studies were published reporting no impact of ESAs on OS
in cancer patients receiving ESAs for CIA (see Table 2 for a
summary). Although the REMS strategy had been in place for a
number of years, by 2017 the FDA determined it was no longer
necessary as prescribers demonstrated acceptable knowledge of
product risks, and drug utilization data indicated appropriate
prescribing of ESAs (US Food and Drug Administration, 2017).
The NCCN guidelines for 2018 reflected the lifting of the REMS
strategy by removing the need to consult REMS when considering
ESA use (National Comprehensive Cancer Network [NCCN],
2018).
FIGURE 1 | South Carolina Medicaid claim data (2002–2012). Reductions in
the number of claims for ESAs were observed over the period 2006–2012,
indicating the “black box” warning resulted in reductions in ESA use. ESA,
erythropoiesis-stimulating agent; NCD, National Coverage Determination;
REMS, Risk Evaluation and Mitigation Strategy.
FIGURE 2 | Electronic health records in Cerner Database: overall annual trend
in the number of visits with ESA use per reporting hospital. The number of
cases for which an ESA was prescribed increased 44% from 240 in 2005 to
346 in 2006. ESA use decreased 13% in 2007 from the previous year; then
use increased by 9% to 328 cases in 2008. The largest reduction was seen in
2009 with a 50% reduction from 2008. Use remained low from then through
2010. ESA, erythropoiesis-stimulating agent; NCD, National Coverage
Determination; REMS, Risk Evaluation and Mitigation Strategy.
Recently, the 2018 ESMO Clinical Practice Guidelines for
the management of anemia and iron deficiency in patients with
cancer (Aapro et al., 2018a) reported no clinical evidence for an
effect of ESAs on stimulating disease progression or relapse when
used within label. For ESA therapy in patients with solid tumors
and hematologic malignancies, the guidelines recommend a
target Hb level of 12 g/dL, initiated at <10 g/dL (symptomatic
anemia) or <8 g/dL (asymptomatic anemia). The guidelines
also advise that iron therapy should be given before and/or
during ESA therapy in the case of absolute or functional iron
deficiency. Backed by evidence from more than 2,500 ESA-treated
patients, the 2018 guidelines also highlight that epoetin alfa is
now indicated by the EMA for the treatment of anemia in low- or
intermediate-1-risk primary myelodysplastic syndrome patients.
The similar safety and efficacy of EMA-approved originator ESA
products and biosimilars is also mentioned.
CLINICAL HISTORY OF ESA USE IN
NEPHROLOGY, LIMITATIONS AND
GUIDELINES
The first ESA approved in Europe for dialysis and non-dialysis
patients with CKD was Eprex R© (epoetin alfa, Ortho Biotech) in
1988, and the first ESA approved for the United States dialysis
market was Epogen R© (epoetin alfa, Amgen, Thousand Oaks, CA,
United States), in 1989. Epogen R© was licensed for “treatment
of anemia associated with chronic renal failure, including
patients on dialysis (end-stage renal disease) and patients not
on dialysis.” Labeling was expanded in 1993 to include a
supplemental indication for the treatment of anemia associated
with cancer chemotherapy. The longer-acting ESA, Aranesp R©
(darbepoetin alfa, Amgen), was licensed in the United States in
2001 (Luksenberg et al., 2004).
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TABLE 2 | Recent studies reporting survival data for ESAs in CIA.
Source Tumor type Patients (n) Results
Untch et al., 2011 Breast 733 No effect – DFS, OS
Nagel et al., 2011 SCLC 73 No effect – PFS, OS
Fujisaka et al., 2011 Lung/Gyn 186 No effect – OS
Moebus et al., 2013 Breast 1284 No effect – RFS, OS
Nitz et al., 2014 Breast 1234 No effect – EFS, OS
Mountzios et al., 2016 Solid tumors 630 No effect – PFS, OS
Leyland-Jones et al., 2016 Met breast 2098 No effect – OS; No effect – PFS (independent review)
Nagarkar et al., 2018 NSCLC 2516 No effect – PFS, OS
CIA, chemotherapy-induced anemia; DFS, disease-free survival; EFS, event-free survival; ESAs, erythropoiesis-stimulating agents; Gyn, gynecological; Met, metastatic;
NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival; SCLC, small cell lung cancer.
Untch et al. (2011): randomized Phase 3 trial of chemotherapy in breast cancer with or without darbepoetin (target Hb 12.5–13 g/dL in darbepoetin-treated patients).
Addition of darbepoetin resulted in no differences in 3-year disease-free survival and OS. Nagel et al. (2011): randomized Phase 2 study involving chemotherapy in limited
or extensive SCLC with or without darbepoetin (target Hb 12–13 g/dL in darbepoetin-treated patients); no differences in PFS or 1-year survival rates reported between
treatment arms. Fujisaka et al. (2011): randomized Phase 3 trial of epoetin beta in patients receiving chemotherapy for lung/gynecological cancer (target Hb under
12 g/dL); no difference in 1-year survival rates reported between ESA treated vs. untreated. Moebus et al. (2013): in a second randomization of an intense dose-dense
chemotherapy arm, outcome in primary breast cancer with or without addition of epoetin alfa (target Hb 12.5–13 g/dL) was studied. Epoetin treatment had no impact on
OS or RFS at median follow-up of 62 months. Nitz et al. (2014): randomized Phase 3 trial in patients with node-positive primary breast cancer receiving chemotherapy
with or without darbepoetin alfa. Initially, Hb levels were maintained between 13 and 14 g/dL, but this was modified to 12 g/dL after the label amendment of 2008. At
39 months, darbepoetin treatment had no impact on either EFS or OS. Mountzios et al. (2016): randomized Phase 3 trial investigating administration of ESAs in patients
with solid tumors and CIA with a median follow-up of 7 years. Patients in one group received prophylactic ESA with iron supplementation (target Hb 14 g/dL). If Hb
levels exceeded 14 g/dL, ESAs were discontinued and resumed when levels were <12 g/dL. In the other group, patients received iron supplementation with ESAs in a
Hb-based manner, initiated only if Hb levels were <11 g/dL during chemotherapy, stopping at 13 g/dL. No differences in DFS, PFS, or OS were reported between the
two groups with respect to the presence or absence of anemia at entry to study, or the manner in which ESAs were given (prophylactic vs. Hb-based). Leyland-Jones
et al. (2016): epoetin alfa in anemic patients receiving chemotherapy for metastatic breast cancer. Patients received either epoetin alfa or best standard of care alongside
chemotherapy. ESA treatment had no effect on OS. Although investigator-determined PFS was reported to be decreased by ESAs, an independent review determined
PFS was not decreased. Nagarkar et al. (2018): evaluated non-inferiority of darbepoetin alfa (DAR) versus placebo for OS and PFS in anemic patients with NSCLC treated
to a 12 g/dL hemoglobin ceiling. Darbepoetin was non-inferior to placebo for OS and PFS and significantly reduced odds of transfusion or hemoglobin ≤ 8 g/dL in anemic
patients with NSCLC receiving myelosuppressive chemotherapy.
In the late 1990s/early 2000s, interesting events underscored
the importance of manufacturing standards in the production
of biologics, with unexpected reports of pure red cell aplasia
primarily associated with subcutaneous Eprex R© in patients
with CKD (Bennett et al., 2004), leading health authorities
in Europe, in 2002, to contraindicate subcutaneous Eprex R© in
patients with CKD (Bennett et al., 2004). Following intensive
investigation, it was considered that a switch to a new
stabilizing agent (polysorbate 80) in 1998 might have resulted
in increased immunogenicity through interaction with leachates
from uncoated rubber stoppers of prefilled syringes, and possible
protein denaturation or aggregate formation resulting from the
polysorbate 80 formulation being more susceptible to stress
conditions (such as insufficient attention to the cold supply
chain) (McKoy et al., 2008). The manufacturers replaced the
rubber stoppers with Teflon R©-coated stoppers and, following
the adoption of processes for its appropriate handling, storage,
and administration, the exposure-adjusted incidence of pure red
cell aplasia decreased worldwide by 83% (Bennett et al., 2004).
By 2006, the contraindication for subcutaneous administration
of Eprex R© in CKD patients had been lifted (Macdougall et al.,
2015).
Throughout the 1990s, clinical practice guidelines for ESAs
were developed and evolved through a focus on evidence-based
medicine. In 1990, the Cooperative Multicenter EPO Clinical
Trial Group reported a Phase 3 trial including more than 300
dialysis patients (Evans et al., 1990). Treatment with epoetin
alfa resulted in improvements in many QoL measures, with
benefits beyond the avoidance of transfusion and iron overload,
including improvements in energy, sleep, and well-being (Evans
et al., 1990). In 1997, the workgroup for the NKF-DOQI
clinical practice guidelines for treating anemia in chronic renal
failure (National Kidney Foundation Dialysis Outcomes Quality
Initiative [NKF-DOQI], 1997) recommended hematocrit levels of
33–36% corresponding to a target Hb level of 11–12 g/dL, which
was higher than the target of 30–33% set by the FDA in 1989;
in 1994, the FDA increased the target hematocrit level range to
30–36% (Ma et al., 1999).
A number of studies in the nephrology arena have been pivotal
in further shaping guidelines. In a double-blind study, Parfrey
et al. (2005) randomized 596 incident hemodialysis patients to
two groups, targeting Hb levels of 13.5–14.5 g/dL or 9.5–11.5 g/dL
(Parfrey et al., 2005). Although the group with higher Hb levels
had a greater incidence of cerebrovascular events, this group
showed an improved QoL outcome (in terms of vitality) (Parfrey
et al., 2005). The Correction of Hemoglobin and Outcomes in
Renal Insufficiency (CHOIR) study of 2006 randomized 1,432
CKD patients to target Hb levels of 13.5 g/dL vs. 11.3 g/dL
with epoetin alfa treatment (Singh et al., 2006). At follow-up,
composite cardiovascular endpoints (including mortality) were
significantly increased in the high-level Hb group. Although
improvements in QoL were seen on correction of anemia, there
was no difference in QoL between the two groups. The authors
concluded that targeting higher Hb levels was associated with
increased risk, with no incremental improvement in QoL. In
Europe, the CREATE study randomized 603 CKD patients to
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early therapy and a target Hb of 13–15 g/dL or to “salvage”
therapy and a target of 10.5–11.5 g/dL, only after the Hb
level had decreased to less than 10.5 g/dL (Drueke et al.,
2006). There were no differences between groups in primary
cardiovascular and survival outcomes, although patients in the
high-level Hb group showed hastened progression to dialysis,
more hypertensive episodes, and improved QoL scores (Drueke
et al., 2006).
The results of CHOIR and CREATE prompted the FDA,
in 2007, to direct manufacturers of ESA products in the
United States to add a “black box” warning recommending the
maintenance of Hb levels within the range of 10–12 g/dL for
anemic patients with CKD (US Food and Drug Administration,
2007b). Also in 2007, the FDA performed an analysis of
CHOIR and also of the Normal Hematocrit Trial, which was a
study involving 1,233 hemodialysis patients with cardiac disease
comparing the survival advantage of achieving and maintaining
normal hematocrit levels (42%) vs. low levels (30%) with epoetin
alfa (Besarab et al., 1998). This trial was stopped early as a
result of the expectation that patients in the normal arm would
not have better outcomes than those in the low-level arm. In
its analysis of CHOIR and the Normal Hematocrit Trial, the
FDA reported an inverse relationship between achieved Hb level
and cardiovascular events, finding that ESAs increased adverse
outcomes when Hb levels changed at a rate greater than 0.5 g/dL
per week, leading the FDA to caution against a rise in Hb
greater than 1 g/dL over a 2-week period (US Food and Drug
Administration, 2007a). A secondary analysis of CHOIR actually
found ESA dose to be the major predictor of AEs, when the
data were adjusted for ESA dose and patients not achieving their
Hb target (Szczech et al., 2008). Those patients achieving target
Hb levels had better outcomes than those who did not, and no
increased risk of higher Hb levels was observed (Szczech et al.,
2008).
The TREAT trial randomized anemic patients with type 2
diabetes and CKD to darbepoetin alfa treatment, with a target
Hb level of 13 g/dL (Group 1), or the administration of placebo
(Group 2), with rescue darbepoetin alfa given to patients in
Group 2 only if Hb levels dropped below 9 g/dL (Pfeffer et al.,
2009). Although there was a significantly higher incidence of
stroke in Group 1, cardiovascular events, death, and QoL scores
were similar for both groups (Pfeffer et al., 2009). Shortly after the
publication of TREAT, the Anemia Working Group of the ERBP
recommended targeting Hb levels of 11–12 g/dL in CKD patients,
and to not intentionally exceed 13 g/dL (Locatelli et al., 2010). In
2011, the FDA removed the target Hb range of 10–12 g/dL, and
recommended that the lowest ESA dose to reduce the need for
transfusions should be used (US Food and Drug Administration,
2011). The following year, the 2012 guidelines of the Kidney
Disease Improving Global Outcomes (Kidney Disease Improving
Global Outcomes [KDIGO], 2012) advised that for adult CKD
patients with Hb concentration ≥10.0 g/dL, ESA therapy should
not be initiated. For maintenance therapy an upper limit of
11.5 g/dL was suggested. In a non-graded recommendation,
KDIGO suggested that individualization of therapy will be
necessary because some patients may have improvements in QoL
at Hb concentrations above 11.5 g/dL and will be prepared to
accept the risks. More recently, the NICE guidelines (National
Institute for Health and Care Excellence [NICE], 2015), and
the Renal Association clinical practice guidelines on anemia of
CKD (Mikhail et al., 2017), both suggested a Hb target range of
10–12 g/dL.
Despite changes in guidance, the question of whether focus
should be directed on avoiding high Hb levels or avoiding
high ESA doses in ESA-resistant patients remained. A meta-
regression analysis published in 2013 examined the association
of ESA dose with adverse outcomes in CKD, independent of the
target or Hb level achieved (Koulouridis et al., 2013). In 12,956
patients, all-cause mortality was associated with higher total-
study-period mean ESA dose and higher first-3-month mean
ESA dose. Total-study-period mean ESA dose and first-3-month
ESA dose remained significant after adjusting for target Hb
or first-3-month mean Hb, respectively. Hypertension, stroke,
and thrombotic events, including dialysis vascular access-related
thrombotic events, were increased with higher total-study-period
mean ESA dose (Koulouridis et al., 2013).
Data continue to be published in the nephrology literature
regarding ESA dose vs. Hb concentration on patient outcomes. In
2016, data from a prospective, non-interventional, multinational
cohort study of 1,039 consecutive patients with advanced or
end-stage renal disease receiving epoetin theta was published
(Lammerich et al., 2016). Data on Hb concentrations and
reportable AEs (RAEs) were collected and the incidence of AEs
examined post hoc according to tertiles for individual mean Hb
concentration (≤10.7, >10.7–11.47, and >11.47 g/dL for low,
intermediate, and high) and mean weekly epoetin theta dosage
(≤62, >62–125, and >125 IU/kg/week for low, intermediate,
and high). Intermediate Hb concentrations were associated with
the lowest incidence of RAEs, and the incidence of ischemic
stroke was 0.6% at both low and intermediate Hb concentrations,
and 1.5% at high Hb concentrations. Patients in the high-
dose/high-Hb group had the greatest risk for cardiovascular
RAEs or ischemic stroke (13.3%), followed by high dose/low
Hb (12.6%) and low dose/low Hb (12.1%). The risks for RAEs
were lowest at low dose/intermediate Hb (5.3%) and high
dose/intermediate Hb (3.8%) (Figure 3). The authors concluded
that the lowest approved, effective dose of epoetin theta should be
used (Lammerich et al., 2016).
THE ADVENT OF BIOSIMILARS
Although the appropriate risk-benefit ratio of ESAs has been
established based on the current labeling and guidelines, access
remains a significant problem in many areas of the world, with
barriers including issues related to insurance coverage, drug
availability, and cost (Lammers et al., 2014; Socinski et al.,
2015). However, biosimilars have reduced development costs
as a result of a less extensive trial program in comparison to
originator products, bringing potential cost savings for patients
and healthcare providers (Blackstone and Joseph, 2013; Singh and
Bagnato, 2015).
An analysis in 2012 compared the cost efficiency of various
originator epoetins vs. a biosimilar, Binocrit R© (epoetin alfa),
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FIGURE 3 | Relationship between reportable adverse events (RAEs) and the
combined effects of hemoglobin (Hb) concentration and dose of epoetin theta
therapy in patients with anemia associated with chronic kidney disease. RAEs
were predefined cardiovascular events selected from the Medical Dictionary
for Regulatory Activities classification system and included cardiac disorders,
cardiac failure, myocardial infarction and ischemic stroke, and respective
subterms. Hb, hemoglobin. Reprinted from Lammerich et al. (2016) with
permission from Elsevier.
across the EU G5 countries (France, Germany, Italy, the
United Kingdom, and Spain) (Aapro et al., 2012). The cost of
ESA treatment for 15 weeks was calculated for a single patient
with cancer receiving chemotherapy; biosimilar epoetin alfa was
calculated to cost €4,643 (30,000 IU) and €6,178 (40,000 IU)
on average. Estimates for originator epoetin alfa treatment were
€7,168 (40,000 IU), and for originator epoetin beta the cost
was €7,389 (30,000 IU), with even higher costs for darbepoetin
alfa. The savings from treating patients with biosimilar epoetin
alfa (40,000 IU) were 13.8% over originator epoetin alfa, 16.4%
over originator epoetin beta, and up to 33% over originator
darbepoetin alfa (Aapro et al., 2012).
Biosimilar competition in the market not only brings lower
prices but can also reduce the cost of originator products. An
analysis of the European market, where various biosimilars have
been available for >10 years, has shown increased treatment
utilization and reduced treatment-day prices following the
introduction of biosimilars in several therapy areas (Quintiles
IMS, 2017). The analysis also shows that, in 2015 in the EU,
biosimilar ESAs accounted for 62% of the market vs. reference
product (Quintiles IMS, 2017). The cost savings associated
with biosimilar use could be reallocated to enhance patient
access to other therapies. For example, a simulation of the
budgetary impact of ESA use in EU G5 countries involved
a hypothetical panel of 100,000 patients, with three models
estimating the number of patients who could be provided with
rituximab, bevacizumab, or trastuzumab therapy from the cost
savings of using biosimilar erythropoietin (Abraham et al., 2014).
Under fixed dosing and assuming 100% conversion, the savings
were over €110 million, translating to an additional ∼17,000
treatments with antineoplastic therapies. As with any ESA, for
safety and economic considerations, biosimilar ESAs should be
used according to the latest guidance and label.
In Europe there are two biosimilar ESAs marketed by different
license holders: epoetin alfa (Abseamed R©, Medice, Iserlohn,
Germany; Binocrit R©, Sandoz, Holzkirchen, Germany; Epoetin
Alfa Hexal R©, Hexal AG, Holzkirchen, Germany), and epoetin zeta
(Retacrit R©, Hospira, Lake Forest, IL, United States; Silapo, Stada
Arzneimittel, Bad Vilbel, Germany). Retacrit R©, for example, was
one of the earliest biosimilar epoetins launched in Europe; post-
marketing and clinical studies have demonstrated clinical efficacy
FIGURE 4 | Timeline of key clinical trials and interventions between 2003 and 2011.
Trial Disease (ESA) Target Hb Clinical outcomes
ENHANCE Head and neck cancer (epoetin beta) >14 g/dL (women); >15 g/dL (men) Shortened PFS with ESA vs. placebo
BEST Breast cancer (epoetin alfa) 12–14 g/dL Lower 12-month OS with ESA vs. placebo
CHOIR CKD (epoetin alfa) 13.5 g/dL vs. 11.3 g/dL Cardiovascular endpoints and mortality increased in
high-level Hb group
CREATE CKD (epoetin beta) Early therapy 13–15 g/dL vs. “salvage”
10.5–11.5 g/dL
Hastened progression to dialysis, more hypertensive
episodes, improved QoL in 13–15 g/dL group
TREAT CKD (darbepoetin alfa) 13 g/dL vs. placebo rescue (below 9 g/dL) Higher incidence of stroke in 13 g/dL group. Cardiovascular
events, death, and QoL similar for both groups
BEST, Breast Cancer Erythropoietin Survival Trial; CHOIR, Correction of Hemoglobin and Outcomes in Renal Insufficiency study; CKD, chronic kidney disease;
CREATE, Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin-beta study; ENHANCE, Erythropoietin in Head and Neck Cancer Trial; NCD,
National Coverage Determination; REMS, Risk Evaluation and Mitigation Strategy; TREAT, Trial to Reduce Cardiovascular Events with Aranesp Therapy.
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and safety in oncology and nephrology indications, and exposure
data reveal a growing population receiving this treatment
(Michallet and Losem, 2016). In May 2018, Epoetin Hospira
was licensed by the FDA for all indications of Epogen/Procrit,
becoming the first and only biosimilar ESA to obtain approval
in the United States. Now finally approved in the United States,
biosimilar ESAs may, as in Europe, provide cost savings and
increase patient access to other novel treatment approaches
(Aapro et al., 2018b).
CONCLUSION
Erythropoiesis-stimulating agents have transformed the
management of anemia in patients with CKD, cancer, and other
indications, with some studies suggesting they improve QoL
in certain subsets of patients with anemia (Evans et al., 1990;
Parfrey et al., 2005; Drueke et al., 2006; Singh et al., 2006; Pfeffer
et al., 2009). The results of key clinical studies have helped
shape guidelines, but ESA use has been potentially impacted
by regulatory actions such as the “black box” warning, REMS
and the NCD (see Figure 4 for timeline). Although target Hb
levels have been a key component of guidance, evolving data
suggest that ESA dose and the speed at which Hb levels change
in response to ESAs are also important considerations when
treating anemic patients (US Food and Drug Administration,
2007a). Indeed, the latest product labeling no longer specifies
a target Hb level, but use of the lowest ESA dose sufficient to
reduce the need for transfusions. Biosimilar ESA products have
been used successfully for many years outside the United States,
with safety and efficacy comparable to originator products,
bringing cost savings to patients and healthcare systems, and
increased access to ESAs and other expensive drugs due to
reallocation of resources. Further research will provide guidance
on individualization of ESA therapy for different patients and
indications so that the optimal benefit to risk ratio may be
achieved.
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